| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
|
|
Victoria, BC, July 28, 2022--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review ("IPR") filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to the LUPKYNIS dosing protocol for lupus nephritis.
|
|
|
|
|
|
|
|
|
|
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
|
|
Victoria, BC, July 18, 2022--Aurinia Pharmaceuticals Inc., a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced the appointment of three seasoned leaders to the Aurinia executive team. Volker Knappertz, MD, will join Aurinia as Executive Vice President, Research and Development, Scott Habig has been named Aurinia's new Chief Commercial Officer, and DeDe Sheel has been hired as Vice President, Investor Relations.
|
|
|
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
